Direct accesses

  • Go to main menu
  • Go to main content
Menu
GenSight GenSight
Search the site
  • Contact
  • Careers
  • You are viewing the website in English en
  • fr
Search the site
  • Whowe are
    • Company
    • Leadership
    • Collaborations
  • Diseaseswe target
    • Diseases we target
    • Leber Hereditary Optic Neuropathy (LHON)
    • Retinitis Pigmentosa (RP)
    • Geographic Atrophy in Dry-AMD
  • Ourtechnologies
    • Technologies we are applying
    • Gene Therapy
    • Mitochondrial Targeting Sequence (MTS)
    • Optogenetics
    • Clinical development Summary
  • Investors
    • Company Overview
    • Financial press releases
    • Investor Newsletters
    • Events & presentations
    • Stock information & Financial agenda
    • Governance
    • Documentation
  • Media

Press Releases

Filter articles using the following links
  • Financial press releases
  • Events & presentations
27 May 2018 - 30 May 2018

ISCAS 2018, Florence, Italy

16 May 2018 - 19 May 2018

21st Annual Meeting ASGCT, Chicago (IL), US

03 April 2018

GenSight Biologics announces topline results from REVERSE Phase III clinical trial of GS010 in patients with Leber Hereditary Optic Neuropathy (LHON)

29 Apr 2018 - 03 May 2018

ARVO Annual Meeting, Honolulu, Hawaï, US

12 Mar 2018 - 14 Mar 2018

BioEurope Spring, Amsterdam, The Netherlands

03 Mar 2018 - 08 Mar 2018

44th NANOS, Hawaii, The Big Island, US

28 February 2018

GenSight Biologics Reports Full Year 2017 Financial Results

20 February 2018

GenSight Biologics announces publication of positive data from Phase I/II trial and long-term follow-up of GS010 in Ophthalmology, the journal of the American Academy of Ophthalmology

25 January 2018

GenSight Biologics reports €55 million 2017 year-end cash position and provides corporate update

25 January 2018

GenSight Biologics Appoints Julio Benedicto as Vice President of Marketing

  • View previous 9 articles
  • 1
  • …
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • …
  • 42
  • View next 9 articles
© 2025 Gensight Biologics
  • Terms of use
  • Sitemap
  • Contact
  • Credits
  • Cookies management
Go back to the page of the page